ERBB2 and breast cancer: Trastuzumab (Herceptin, Genentech), a recombinant monoclonal antibody against HER2, specifically binds to the extracellular portion of HER2, inhibits the proliferation of human cancer cells and becomes an important therapeutic option for patients with HER2 positive breast cancer.